<DOC>
	<DOCNO>NCT01026402</DOCNO>
	<brief_summary>The main purpose study establish safe dose drug provide information potential side effect drug may cause collect data patient 's cancer respond drug . The study also assess blood level action AZD2014 body period time indicate whether drug effect type cancer patient .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics ( PK ) Preliminary Efficacy AZD2014</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histological cytological confirmation solid , malignant tumour refractory standard therapy standard therapy exist At least one lesion ( measurable and/or nonmeasurable ) accurately assessed baseline computerise tomography ( CT ) magnetic resonance imaging ( MRI ) plain Xray suitable repeat assessment World Health Organisation performance status 02 deterioration previous 2 week minimum life expectancy 12 week Patients severe laboratory abnormality haematology , liver renal function . Also treatment haemopoietic growth factor allow within two week prior first dose study drug Patients abnormal fast glucose , type I uncontrolled type II diabetes Patients severe cardiac condition ischemia , impair ventricular function arrhythmia , evidence severe uncontrolled systemic current unstable uncompensated respiratory cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>advanced solid malignancy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>AZD2014</keyword>
	<keyword>mTor kinase inhibitor</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>